Briancon S, Thisse J Y, Watrin H, Feintrenie X, Lamaze R, Lamy P
Presse Med. 1983 Dec 3;12(44):2805-8.
Forty-three patients with small-cell bronchial carcinoma were treated with sequential combination chemotherapy of the CMC-VAP type alternating every 6 weeks. Toxicity affected mostly blood cells and occurred during induction. The response rate was 60% in circumscribed forms with a median survival of 15 months, and 30% in diffuse forms with a median survival of 6 months. The value of alternating protocols and the place of radiotherapy are discussed in the light of these results.
43例小细胞支气管癌患者接受了每6周交替进行的CMC-VAP型序贯联合化疗。毒性主要影响血细胞,且发生在诱导期。局限性病变的缓解率为60%,中位生存期为15个月;弥漫性病变的缓解率为30%,中位生存期为6个月。根据这些结果对交替方案的价值和放疗的地位进行了讨论。